
    
      This study is an open-label extension study for subjects who have completed 14 days of
      treatment in protocol ACH443-014A and meet all inclusion and exclusion criteria. Elvucitabine
      treatment (10mg) will begin on Day 1 (Day 15 following completion of protocol ACH443-014A)
      for all consented subjects in combination with background ART as determined by the principal
      investigator. Subjects will have clinical and laboratory assessments every 2 weeks for the
      first 8 weeks and then every 4 weeks to week 48.
    
  